



POF 1262-A  
(INDIGENOUS SUPPLIES)

Government of Pakistan  
PAKISTAN ORDNANCE FACTORIES  
TENDER ENQUIRY  
(Therapeutic Goods / Pharmaceuticals)

To

M/s

---

---

---

---

Dear Sirs,

Reference : TENDER ENQUIRY NO. 0002/HOSP/LP/56/MEDICINE

DATED 21-04-2026

You are requested to submit sealed quotations for the item(s) noted in the Schedule to the Tender. Offer should be sent duly sealed in a single stage two envelopes. Fax offer received before opening of Tender is acceptable. Please note the following instructions for filling the tender:-

**1. SUBMISSION OF TENDER**

1.1 Tenders will be opened at 10:00 hours on 21-05-2026 in Bid Centre adjacent to Rabita Hall POF Wah Cantt. Quotation must be submitted electronically on [www.ebidding.pof.gov.pk](http://www.ebidding.pof.gov.pk) (otherwise offer will not even be entertained) as well as in hard form (duly sealed in envelopes) before 30 minutes of opening time. The tender received late will not be entertained. You may witness the opening of the tender if you so desire. If a representative is deputed, he should bring a letter of authority from you.

1.2 Only one tender should be included in one envelope. The outside of the envelope should be inscribed with:-

Tender Enquiry No: 0002/HOSP/LP/56/MEDICINE DT. 21-04-2026  
Tender to be opened on: 21-05-2026  
Address as follows:-  
(www.ebidding.pof.gov.pk) BID CENTER  
ADJACENT TO RABITA HALL  
POFs, WAH CANTT.

1.3 If envelope does not indicate reference of T.E or received late the same may be returned un-opened.

**2. GENERAL INSTRUCTIONS REGARDING PREPARATION OF QUOTATIONS (THERAPEUTIC GOODS)**

2.1 For MEDICINE, the prices should be filled in column 6 and delivery date in relevant column of the schedule to this Tender Enquiry. The undertaking should be signed at the bottom of the Schedule which shall form the Quotation. You may use a separate sheet if necessary.

2.2 For MEDICINE, the bid shall comprise a single package containing two separate envelopes. Each envelope shall contain separately the Technical offer and the Commercial offer:-

**Part I "Technical Offer":** It should exclusively give technical details and literatures/brochures of the MEDICINE; validity date; delivery schedule;

Cont....P-2

and signed undertaking given on the schedule to this Tender Enquiry. It must not indicate price, costs etc.

**Part II "Commercial Offer":** It should indicate the commercial terms e.g. price, terms of payment, mode of payment, mode of supply.

Each part should be placed in a separate sealed cover. The envelopes should be inscribed with Part I "Technical Quotation without Price" and Part II "Commercial Quotation with Price".

- 2.3 The technical quotation must remain valid for, at least 90 days from the date of opening of tenders.
- 2.4 The quotation should hold good for any reduced or enhanced quantities without notice.
- 2.5 In the event of non-acceptance of offer, intimation may be given to the tenders on their request.
- 2.6 Conditional offers or alternative offers are likely to be ignored.
- 2.7 Quotations should be based on:-

F.O.R. station of despatch basis, i.e. delivered free on rail, inclusive of packing and forwarding charges. The stores will be booked under Military Credit Note, to be provided by the purchaser.

Free delivery at POF's hospital at WAH CANTT

In this case Octroi duty if any, will be payable by the supplier.

- 2.8 Taxes and Duties etc. where applicable, must be shown separately, quoting references to Registration No. in cases of Sales Tax and relevant authority in the case of others. Offers without these clarifications and inclusive of Taxes and Duties may be ignored.
- 2.9 Taxes and duties levied on or after Tender opening date or on or after the date offer was signed and despatched will be allowed to include in the offered rates.
- 2.10 "Suppliers will furnish a certificate, issued by Excise & Taxation deptt., that he has cleared all Professional Tax payable by him" offers received without this certificate will be rejected.
- 2.11 If the requisite information is not furnished on the T.E forms or offer received is not conformity with the requirement of T.E such offer shall be ignored.
- 2.12 The supplier will render necessary information regarding hazardous effects on environment of the material/products supplied by them, in their quotations and shipping/despatch documents.

### 3. INSPECTION

- 3.1 Supplies shall be subject to the inspection and acceptance by the competent inspection authority nominated by the Purchaser, who will arrange it at his own cost. Inspection facilities such as tools, test equipment, instruments etc will, however, be provided by the Suppliers in accordance with the relevant specifications.
- 3.2 Where considered necessary by the Purchaser, the stores may be obtained on Warranty/Guarantee subject to inspection on receipt. Rejected stores will be removed and replaced with the acceptable stores by the Supplier at his own expense, within a specified time.

Contd...P-3

4. TENDER FEE

The tender must be accompanied with a non-refundable tender fee Rs 500/- by means of a crossed postal order / pay order in favour of: **Director Admin POF WAH CANTT.**

4.1 TENDER SAMPLE

Where required, offer must accompany tender sample., strictly according to the description and specification given in Tender Enquiry. Offer not accompanied by tender sample will NOT be entertained excepting the established and reputable firms who have either previously satisfactorily supplied the same or similar stores or have submitted an acceptable sample thereof against previous T.E.

5. BID MONEY

Bid Money as per following detail, should accompany the tender in the shape of Deposit at Call Receipt / Pay Order / Banker's Cheque, from a scheduled Bank drawn in favour of:- **DY COMMANDANT POF HOSPITAL WAH CANTT.**

- 5.1 Registered / indexed firms incl foreign firms - 2% of quoted value subject to max ceiling of Rs. 0.50 M.
- 5.2 Registered / un-indexed firms incl foreign firms - 03% of quoted value subject to max ceiling of Rs. 0.75 M.
- 5.3 Unregistered Firms incl foreign firms - 5% of quoted value subject to max ceiling of Rs. 1.00 M.
- 5.4 Govt. organization/ production units/state owned enterprises/ welfare projects of Svcs HQ - Rs. 0.50 M.
- 5.5 Earnest money will be returned to un successful (less first three lowest quote firms) bidders on opening of commercial offer.
- 5.6 Earnest / bid money will be returned to successful bidder on submission of unconditional BG.

6. ACCEPTANCE OF OFFERS.

6.1 POF Hospital may reject all bids or proposals at any time period to the acceptance of the bid or proposals, but is not required to justify grounds for its rejection. POF shall incur no liability towards suppliers or contractors who have submitted bids or proposals.

6.2 PERFORMANCE BOND

- (a) The successful bidders shall provide performance guarantee which shall not exceed 10% of the contract amount in form of **unconditional Bank Guarantee / CDR** from a scheduled Bank within 07 working days from issuance of LOI strictly. The performance Bond will be in favour of CMA(POF) Wah Cantt. It will be returned on satisfactory completion of contract.
- (b) If the Supplier fails to furnish the Performance Bond within the specified time, such failure will constitute a breach of the contract and the Purchaser shall be entitled to make other arrangements for purchase of the stores at the risk and expense of the Supplier.

Contd....p-4

6.3 Performance Bond from State owned organizations may be waived off at the discretion of the Purchaser.

6.4 FAILURE TO SUPPLY THE STORES

All deliveries must be completed by the specified date. In case of failure to deliver the stores within the scheduled time should have arisen from "Force Majeure", which the purchaser may admit as reasonable ground for further time, he will allow such additional time as he may consider to have been required by the circumstances of the case. Otherwise, he will be entitled, at his discretion, to cancel the contract; and/or claim liquidated damages upto 2% but not less than 1% of the contract price of the items and their quantities for each and every month or part of a month, beyond the specified delivery date, during which these may not be delivered, subject to a maximum of 10% of the total contract value of the particular stores which remained unsupplied either in part or in full; or, to purchase, from elsewhere, the unsupplied stores at the risk and cost of the supplier.

6.5 PAYMENT

Payment will be made by the CMA(POF) through crossed cheques on receipt/ acceptance of stores on our prescribed bill form supported by receipt voucher on part/full supply basis.

(a) Payment of duties/Taxes including professional tax (where applicable) must be supported by proof of having paid these to concerned Govt. Taxation Deptt.

7. SECURITY OF INFORMATION

The tenderer and his employees must not communicate any information relating to the sale/purchase of stores under this enquiry to any person other than the manufacturer or to any press or agent not authorised in writing by POFs to receive it.

Please return the Schedule to the Tender duly signed by the specified date, alongwith the specifications, drawings etc. if any, enclosed herewith - if you are unable to quote.

**WARNING** In case the firm abstain from making offers or fail to return/ acknowledge the tender form by the specified date on three consecutive occasions, no further tender enquiry may be issued to them and their names would liable to be removed from the approved list.

Yours faithfully

DR. MEHFISHAN FEROZE

DY. COMMANDANT

for PAKISTAN ORDNANCE FACTORIES

## PAKISTAN ORDNANCE FACTORIES

SCHEDULE TO TENDER NO. 0002/HOSP/LP/56/MEDICINE

21-APR-26

## (1) FOR MATERIALS

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Item No.	Description with Specs. etc.	Manufacturer	Unit	Qty	Quoted Rate (Rs.)	GST (Rs.)	Total Price (Rs.)
Indent No. 0002/LP/HOSP/56 Dated 02-01-2026							
001	ABIRATERONE ACETATE 250 MG TAB/XBERA 250 MG TAB Spec: ABIRATERONE ACETATE	HIMMEL/CIPLA OR EQUIVALENT	NO	8000			
002	ACLASTA 5 MG INJ/MACDRONIC 5 MG INJ/ZIVALO 5 MG INJ Spec: ZOLEDRNIC ACID	NOVARTIS/MACTER/SAMI OR EQUIVALENT	VIAL	38			
003	ADRIBLASTINA 10 MG INJ/ADRIIM 10 MG INJ/RUBIDOX 10 MG INJ Spec: DOXORUBICIN	PFIZER/ATCO/ROTEX-ONCOVANZ OR EQUIVALENT	VIAL	105			
004	ADRIBLASTINA 50 MG INJ/ADRIIM 50 MG INJ/RUBIDOX 50 MG INJ Spec: DOXORUBICIN	PFIZER/ATCO/ROTEX-ONCOVANZ OR EQUIVALENT	VIAL	195			
005	ALIMTA 100 MG INJ/PEMSOH 100 MG INJ Spec:	ELI LILLY/A.J. MIRZA OR EQUIVA	VIAL	20			
006	ALIMTA 500 MG INJ/PEMSOH 500 MG INJ Spec: PEMETREXED DISODIUM	ELI LILLY/A.J. MIRZA OR EQUIVALENT	VIAL	10			
007	APREON 80/125 MG CAP Spec: APREPITANT	FEROZSONS OR EQUIVALENT	PACK	50			
008	ARIMIDEX 1 MG TAB/GENEPLEX 1 MG TAB Spec: ANASTROZOLE	LC (EX ICI)/UMAR PHARMA OR EQUIVALENT	NO	10000			
009	AROMASIN 25 MG TAB/EXEMESTANE NORMON 25 MG TAB Spec: EXEMESTANE	PFIZER/MERIXIL OR EQUIVALENT	NO	670			
010	AVASTIN 100 MG / 4 ML INJ Spec: BEVACIZUMAB	ROCHE OR EQUIVALENT	VIAL	75			
011	AVASTIN 400 MG / 16 ML INJ Spec: BEVACIZUMAB	ROCHE OR EQUIVALENT	VIAL	90			
012	BENDALAB 100 MG INJ/BENDAMUSTINE HCL 100 MG INJ Spec: BENDAMUSTINE HCL	LDS PHARMA/ATCO OR EQUIVALENT	VIAL	60			
013	BITAMID 50 MG TAB/CASODEX 50 MG TAB Spec: BICALUTAMIDE	PHARMASOL/ICI OR EQUIVALENT	NO	5500			
014	BLASVIN 10 MG INJ/VINBLAS 10 MG INJ Spec: VINBLASTINE	PHARMASOL/PHARMEDIC OR EQUIVALENT	VIAL	15			
015	BLEOMYCIN 15 MG INJ/BLEOTEX 15 MG INJ Spec: BLEOMYCIN	PHARMEDIC/ONCOVANZ OR EQUIVALENT	VIAL	12			

## PAKISTAN ORDNANCE FACTORIES

SCHEDULE TO TENDER NO. 0002/HOSP/LP/56/MEDICINE

21-APR-26

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Item No.	Description with Specs. etc.	Manufacturer	Unit	Qty	Quoted Rate (Rs.)	GST (Rs.)	Total Price (Rs.)
016	BORTEZOMIB 3.5 MG INJ/EGYBORT 3.5 MG INJ Spec: BORTEZOMIB	HIMMEL PHARMACEUTICALS/R EVIVE OR EQUIVALENT	VIAL	20			
017	CAFOL 100 MG INJ Spec: CALCIUM FOLINATE (CALCIUM LEUCOVORIN)	GRATON PHARMA OR EQUIVALENT	VIAL	40			
018	CAPCITA 500 MG TAB/XELODA 500 MG TAB Spec: CAPECITABINE	PHARMASOL/ROCHE OR EQUIVALENT	NO	20000			
019	CARBOL 150 MG INJ/CARPSOL 150 MG INJ/KEMOCARB 150 MG INJ Spec: CARBOPLATIN	HELIX PHARMA/PFIZER/ATCO OR EQUIVALENT	VIAL	180			
020	CARBOL 450 MG INJ/CARBOSOL 450 MG INJ Spec: CARBOPLATIN	HELIX PHARMA/PHARMASOL OR EQUIVALENT	VIAL	30			
021	CISPATIN 50 MG INJ/CISPLATIN 50 MG INJ Spec: CISPLATIN	PHARMASOL/ATCO OR EQUIVALENT	VIAL	45			
022	CRISVIN 1 MG INJ/VINCRISTINE 1 MG INJ Spec: VINCRISTINE	PHARMASOL/PHARMACEMIE OR EQUIVALENT	VIAL	105			
023	CYCLOMIDE 1 GM INJ/ONCOFOS 1 GM INJ Spec: CYCLOPHOSPHAMIDE	PHARMADIC/ROTEX PHARMA OR EQUIVALENT	VIAL	165			
024	CYCLOMIDE 500 MG INJ/ENDOXAN 500 MG INJ Spec: CYCLOPHOSPHAMIDE	PHARMADIC/AGP OR EQUIVALENT	VIAL	30			
025	DAXOTEL 20 MG INJ/DOCETAXEL 20 MG INJ/DOTAXOL 20 MG INJ Spec: DOCETAXEL	ATCO/AL-HABIB/PHARMASOL OR EQUIVALENT	VIAL	160			
026	ELTROM 25 MG TAB/REVLADE 25 MG TAB Spec: ELTROMBOPAG	PHARMASOL/NOVARTIS OR EQUIVALENT	NO	1845			
027	ELTROM 50 MG TAB/REVLADE 50 MG TAB Spec: ELTROMBOPAG	PHARMASOL/NOVARTIS OR EQUIVALENT	NO	1500			
028	EMESSON 8 MG TAB/ONSET 8 MG TAB Spec: ONDANSETRON	HIGHNOON/PHARMEDIC OR EQUIVALENT	NO	2500			
029	ENERCEPT 25 MG INJ/MOMENTUM 25 MG INJ Spec: ETANRACEPT	GETZ/MACTER OR EQUIVALENT	VIAL	180			
030	FEMAPLEX 2.5 MG TAB/FEMARA 2.5 MG TAB Spec: LETROZOLE	UMAR PHARMA/NOVARTIS OR EQUIVALENT	NO	12000			

## PAKISTAN ORDNANCE FACTORIES

SCHEDULE TO TENDER NO. 0002/HOSP/LP/56/MEDICINE

21-APR-26

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Item No.	Description with Specs. etc.	Manufacturer	Unit	Qty	Quoted Rate (Rs.)	GST (Rs.)	Total Price (Rs.)
031	FILGEN 300 MCG INJ/NEOFIL 300 MCG INJ Spec: FILGRASTIN	BF BIOSCIENCES/SAMI OR EQUIVALENT	VIAL	2000			
032	FLURACIL 500 MG INJ/ONCOFU 500 MG INJ Spec: FLUOROURACIL	BIOPHARMA/ROTEX PHARMA OR EQUIVALENT	VIAL	30			
033	GEMCITABINE 1 GM INJ/GEMITA 1 GM INJ/GEMZAR 1 GM INJ Spec: GEMCITABINE	NOVARTIS/ATCO/ELLY LILLY OR EQUIVALENT	VIAL	100			
034	GEMCITABINE 200 MG INJ/GEMZAR 200 MG INJ/ZEFEI 200 MG INJ Spec: GEMCITABINE	NOVARTIS/ELLY LILLY/AJM PHARMA OR EQUIVALENT	VIAL	120			
035	GLIVEC 100 MG TAB/IMATIB 100 MG TAB Spec: IMATINIB MESYLATE	NOVARTIS/A.J.MIRZA OR EQUIVALENT	NO	2000			
036	GLIVEC 400 MG TAB/GVEC 400 MG TAB Spec: IMATINIB MESYLATE	NOVARTIS/CROWN PHARMA / ROTEX PHARMA OR EQUIVALENT	NO	2000			
037	HERCEPTIN 440 MG / 20 ML INJ/TRAZIMERA 440 MG / 20 ML INJ Spec: TRASTUZUMAB	ROCHE/PFIZER OR EQUIVALENT	VIAL	60			
038	HERCEPTIN 600 MG INJ Spec: TRASTUZUMAB	ROCHE OR EQUIVALENT	VIAL	50			
039	HYDRA 500 MG CAP/HYDROXA 500 MG CAP Spec: HYDROXYUREA	MEDINET/PHARMASOL OR EQUIVALENT	NO	3200			
040	INIBCO 4 MG INJ/ZOLDRONIC 4 MG INJ/ZOMETA 4 MG INJ Spec: ZOLEDRONIC ACID	ONCOVANZ/NABI QASIM/NOVARTIS OR EQUIVALENT	VIAL	300			
041	INTAXEL 100 MG INJ/PACLITAXEL 100 MG INJ Spec: PACLITAXEL	ATCO/CARE PHARMA OR EQUIVALENT	VIAL	375			
042	INTAXEL 150 MG INJ/PETAXEL 150 MG INJ Spec: PACLITAXEL	ATCO/PHARMASOL OR EQUIVALENT	VIAL	260			
043	IRINOTECAN 100 MG INJ/IRINOTEL 100 MG INJ Spec: IRINOTECAN HCL	NOVARTIS/ATCO OR EQUIVALENT	VIAL	50			
044	KISQALI 200 MG TAB Spec: RIBOCICLIB	NOVARTIS OR EQUIVALENT	NO	1600			
045	KUNYRIN 50 MG INJ Spec: CALCIUM FOLINATE (CALCIUM LEUCOVORIN)	AL-HABIB PHARMA OR EQUIVALENT	VIAL	40			

## PAKISTAN ORDNANCE FACTORIES

SCHEDULE TO TENDER NO. 0002/HOSP/LP/56/MEDICINE

21-APR-26

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Item No.	Description with Specs. etc.	Manufacturer	Unit	Qty	Quoted Rate (Rs.)	GST (Rs.)	Total Price (Rs.)
046	LECTRUM 3.75 MG INJ/LORELLIN 3.75 MG INJ Spec: LEUPRORELIN ACETATE	NOVARTIS/AMGOMED OR EQUIVALENT	VIAL	550			
047	LECTRUM 7.5 MG INJ Spec: LEUPRORELIN ACETATE	NOVARTIS OR EQUIVALENT	VIAL	50			
048	LINAMIDE 10 MG CAP/RELIDOMIDE 10 MG CAP Spec: LENALIDOMIDE	HIMMEL PHARMACEUTICALS/H ELIX PHARMA OR EQUIVALENT	NO	2000			
049	LORELIN DEPOT 11.25 MG INJ/LUCRIN 11.25 MG INJ Spec: LEUPRORELIN ACETATE	MEDISURE LABS/ABBOTT OR EQUIVALENT	VIAL	20			
050	METHOTREXATE 50 MG INJ/TREXATE 50 MG INJ Spec: METHOTREXATE	BIOPHARMA/PHARMASOL OR EQUIVALENT	AMPULE	80			
051	NEXAGET 200 MG TAB/SONIB 200 MG TAB Spec: SORAFENIB	ONCOVANZ-ROTEX PHARMA/PHARMASOL OR EQUIVALENT	NO	4000			
052	NITONIB 200 MG TAB/TASIGNA 200 MG TAB Spec: NILOTNIB	PHARMASOL/NOVARTIS OR EQUIVALENT	NO	10000			
053	NOLVADEX 10 MG TAB Spec: TAMOXIFEN	LCI (EX ICI) OR EQUIVALENT	NO	30000			
054	ONCO BCG 40 MG INJ/ONCOTICE 40 MG INJ Spec: TICE BCG	CIPLA/OBS PHARMA OR EQUIVALENT	NO	100			
055	ONSET 4 MG INJ/ONTIV 4 MG INJ Spec: ONDANSETRON	PHARMEDIC/SAMI OR EQUIVALENT	VIAL	1500			
056	ONSET 8 MG INJ/ZEDRON 8 MG INJ Spec: ONDANSETRON	PHARMEDIC/SHAIGAN OR EQUIVALENT	VIAL	30000			
057	OXALIPATIN 100 MG INJ/OXALIPLATIN AQVIDA 100 MG INJ Spec: OXALIPLATIN	AJM PHARMA/HIMMEL OR EQUIVALENT	VIAL	50			
058	OXALIPLATIN AQVIDA 50 MG INJ/OXALTIE 50 MG INJ Spec: OXALIPLATIN	HIMMEL/FEROZSONS OR EQUIVALENT	VIAL	330			
059	RISTOVA 100 MG INJ Spec: RITUXIMAB	ROCHE OR EQUIVALENT	VIAL	50			
060	RISTOVA 500 MG INJ Spec: RITUXIMAB	ROCHE OR EQUIVALENT	VIAL	70			

## PAKISTAN ORDNANCE FACTORIES

SCHEDULE TO TENDER NO. 0002/HOSP/LP/56/MEDICINE

21-APR-26

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Item No.	Description with Specs. etc.	Manufacturer	Unit	Qty	Quoted Rate (Rs.)	GST (Rs.)	Total Price (Rs.)
061	TECENTRIQ 1200 MG INJ Spec: ATEZOLIZUMAB	ROCHE OR EQUIVALENT	VIAL	40			
062	TEMOMIDE 100 MG TAB/TEMOZOLAMIDE 100 MG TAB Spec: TEMOZOLAMIDE	CLARITY BIO SCIENCES/CIPLA OR EQUIVALENT	NO	200			
063	THROMBOMAX 12 MIU / 1.5 MG INJ/TOPMAGA 1.5 MG INJ Spec: RECOMBINANT HUMAN INTERLEUKIN-11	AMGOMED/MERAXIL OR EQUIVALENT	VIAL	90			
064	VOTRIENT 400 MG TAB Spec: PAZOPANIB	NOVARTIS OR EQUIVALENT	NO	1000			

GRAND TOTAL (Rs):

(2) For Plant & Machinery:  
Specification:-

## (3) Special Conditions

- 01 Only one rate should be quoted in local currency i.e, Rs / Unit.
- 02 The delivered medicines/store which are subsequently found un-registered or nearing the expiry date at any stage during the currency of the contract, shall have to be replaced by the supplier at its on expense.
- 03 Quotation must remain valid for 90 days from commercial opening.
- 04 Sample are mandatory on FOC basis for alternate brands alongwith tech. quotation otherwise offer will not be considered.
- 05 Each delivery challan must bear batch No, Date of manufacture and date of expiry of delivered Store alongwith mandatory information to Purchase Section.
- 06 S.Tax will not be paid by POF Hospital in accordance with S.No.52-A in 6th schedule of S.Tax Act-1990 through Finance Bill. 2008 being teaching hospital over 500 beds.
- 07 The supplies must be of fresh manufacture and must possess at least 85% to 90% of the labeled life on receipt by the consignee.
- 08 The supplier will make sure that the medicines/Store are not sub-standard and have prescribed life printed on packing. The medicines shall be delivered in original sealed packing/containers from the manufacturers.
- 09 The supplier will be bound to supply the store within Delivery Period.
- 10 Brand name must clearly be Mentioned against which the rate is quoted.
- 11 Supplier must ensure the quality of items supplied. In case of any complaint from end user, the supplier will replace the item on his own expense.
- 12 Supplier will provide authorized distribution letter of their manufacturer/ importer (notarized copy from related Embassy and rep must generate the original of same at the time of tender opening (Technical)
- 13 Delivery is required for FY 2026-27.
- 14 Only registered suppliers (with sales tax & income tax deptt) who are on active taxpayer list (ALT) of FBR are elligible to supply goods/services to government departments. If any registered suppliers is not ACTIVE on ATL, his payment will be stopped till the mandatory returns and appearance on ATL of FBR.
- 15 Firm should be registered with SECP (Securities & Exchange Commission of Pakistan) registration certificate be enclosed with T.E documents.
- 16 Tender Received Without Bid Money Will Be Rejected.

## PAKISTAN ORDNANCE FACTORIES

SCHEDULE TO TENDER NO. 0002/HOSP/LP/56/MEDICINE

21-APR-26

- 17 Supplier will provide drug testing certificate of gouted medicines alongwith the tender documents.
- 18 Samples of Therapeutic goods being supplied by the firm may be got tested by procuring agency from any reputable Lab at the expense of the firm at any stage during currency of contract/expiry of medicines, if required .
- 19 Supplier will ensure / provide documentary evidence at the time of payment that stamp duty @ 0.25% of total value of contract have been paid.
- 20 The offers of firms, with poor past performance, will be rejected.
- 21 PPRA Criteria for Technical Evaluation of Bids is attached as Annex-"A".


**(4) Undertaking**

Should our offer be accepted, we hereby undertake to supply the stores/render the services contracted on the basis of General Conditions of Contract embodied in Form POF 1281, and to deposit the performance bond in the shape of unconditional Bank Guarantee / CDR within the prescribed time, failing which it will constitute a breach of contract, and POF will have the right to purchase the stores/services elsewhere at our risk and cost.

Place \_\_\_\_\_  
 Date \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

Signature of the Tenderer \_\_\_\_\_  
 Name \_\_\_\_\_  
 Position \_\_\_\_\_  
 Address \_\_\_\_\_  
 Income Tax G.I.R. No \_\_\_\_\_  
 Official Stamp \_\_\_\_\_

SECTION VI- EVALUATION AND QUALIFICATION CRITERIA  
(SAMPLE)



### Sample Qualification and Technical Evaluation criteria

Parameters	Detail	Total marks	Remarks																					
1	Market experience in quoted items <table border="1" style="margin-left: 20px;"> <tr> <td>i.</td> <td>Above 5 years</td> <td>5</td> </tr> <tr> <td>ii.</td> <td>3-5 yrs</td> <td>3</td> </tr> <tr> <td>iii.</td> <td>1-2 yrs</td> <td>1</td> </tr> </table>	i.	Above 5 years	5	ii.	3-5 yrs	3	iii.	1-2 yrs	1	5	In case of authorize supplier, original manufacturer experience shall be attached. Experience less than 1 year are not eligible												
i.	Above 5 years	5																						
ii.	3-5 yrs	3																						
iii.	1-2 yrs	1																						
2	Past performance <table border="1" style="margin-left: 20px;"> <tr> <td colspan="3">Major institution served</td> </tr> <tr> <td>i.</td> <td>Above 10</td> <td>10</td> </tr> <tr> <td>ii.</td> <td>8 to 10</td> <td>8</td> </tr> <tr> <td>iii.</td> <td>5 to 7</td> <td>6</td> </tr> <tr> <td>iv.</td> <td>2 to 4</td> <td>4</td> </tr> <tr> <td>v.</td> <td>1</td> <td>2</td> </tr> <tr> <td>vi.</td> <td>No institution served</td> <td>0</td> </tr> </table>	Major institution served			i.	Above 10	10	ii.	8 to 10	8	iii.	5 to 7	6	iv.	2 to 4	4	v.	1	2	vi.	No institution served	0	10	Institution include Government department, hospitals and private hospitals
Major institution served																								
i.	Above 10	10																						
ii.	8 to 10	8																						
iii.	5 to 7	6																						
iv.	2 to 4	4																						
v.	1	2																						
vi.	No institution served	0																						
3	Credibility and certification <table border="1" style="margin-left: 20px;"> <tr> <td>i.</td> <td>Valid GMP certificate</td> <td>5</td> </tr> <tr> <td>ii.</td> <td>Valid ISO certification</td> <td>3</td> </tr> <tr> <td>iii.</td> <td>Any other relevant certification</td> <td>2</td> </tr> </table>	i.	Valid GMP certificate	5	ii.	Valid ISO certification	3	iii.	Any other relevant certification	2	10	GMP issued by Drug Regulator Authority of Pakistan is required. Therapeutic goods which are not Registered with DRAP are not eligible.												
i.	Valid GMP certificate	5																						
ii.	Valid ISO certification	3																						
iii.	Any other relevant certification	2																						
4	Financial Status <table border="1" style="margin-left: 20px;"> <tr> <td>i.</td> <td>Last year audited balance sheet</td> <td>5</td> </tr> <tr> <td>ii.</td> <td>Tax returns last 3 years</td> <td>3</td> </tr> <tr> <td>iii.</td> <td>Bank certificates about wealth, reputation and liquidity status that bidders have never defaulted</td> <td>2</td> </tr> </table>	i.	Last year audited balance sheet	5	ii.	Tax returns last 3 years	3	iii.	Bank certificates about wealth, reputation and liquidity status that bidders have never defaulted	2	10	Bidder can provide more than one certificate which indicates about bidder's financial wealth, liquidity status, reputation that they have never defaulted in financial transactions and letter												
i.	Last year audited balance sheet	5																						
ii.	Tax returns last 3 years	3																						
iii.	Bank certificates about wealth, reputation and liquidity status that bidders have never defaulted	2																						

				of credits.																				
5	Production capacity	Per day production capacity against the quoted items against total advertised quantity <table border="1"> <tr> <td>i</td> <td>1.6-2%</td> <td>5</td> </tr> <tr> <td>ii</td> <td>1.1-1.5%</td> <td>3</td> </tr> <tr> <td>iii</td> <td>1%</td> <td>2</td> </tr> <tr> <td>iv</td> <td>Less</td> <td>0</td> </tr> </table>	i	1.6-2%	5	ii	1.1-1.5%	3	iii	1%	2	iv	Less	0	5									
i	1.6-2%	5																						
ii	1.1-1.5%	3																						
iii	1%	2																						
iv	Less	0																						
6	Product sample	Sample will be examine per following parameters a) Labeling and packing rule 1986 b) Outer packing c) Inner packing d) Physical appearance <table border="1"> <tr> <td>i</td> <td>Excellent</td> <td>5</td> </tr> <tr> <td>ii</td> <td>Good</td> <td>3</td> </tr> <tr> <td>iii</td> <td>Satisfactory</td> <td>2</td> </tr> <tr> <td>iv</td> <td>Unsatisfactory</td> <td>0</td> </tr> </table>	i	Excellent	5	ii	Good	3	iii	Satisfactory	2	iv	Unsatisfactory	0	5	Products that 100% comply with the advertised specification shall be considered for evaluation								
i	Excellent	5																						
ii	Good	3																						
iii	Satisfactory	2																						
iv	Unsatisfactory	0																						
7	Technical staff	<table border="1"> <tr> <td rowspan="2">i</td> <td rowspan="2">Plant manager</td> <td>PHD/ IPHIL</td> <td>2</td> </tr> <tr> <td>Pharm</td> <td>1</td> </tr> <tr> <td rowspan="2">i</td> <td rowspan="2">Production manger</td> <td>PHD/ IPHIL</td> <td>2</td> </tr> <tr> <td>2</td> <td>1</td> </tr> <tr> <td>i</td> <td>Quality assurance manger</td> <td>Pharm / MSc chemistry</td> <td>1</td> </tr> <tr> <td>i</td> <td>Quality control manager</td> <td>Pharm / MSc chemistry</td> <td>1</td> </tr> </table>	i	Plant manager	PHD/ IPHIL	2	Pharm	1	i	Production manger	PHD/ IPHIL	2	2	1	i	Quality assurance manger	Pharm / MSc chemistry	1	i	Quality control manager	Pharm / MSc chemistry	1	6	Bidder is required to attach relevant attested degree and appointment letter of the concerned staff
i	Plant manager	PHD/ IPHIL			2																			
		Pharm	1																					
i	Production manger	PHD/ IPHIL	2																					
		2	1																					
i	Quality assurance manger	Pharm / MSc chemistry	1																					
i	Quality control manager	Pharm / MSc chemistry	1																					

8	Bioequivalence study of the quoted products	Availability of bioequivalence study	3													
9	Ranking of firm	Current ranking according to Sales (pharmaceutical sales index)	6	Attach certificate of current ranking												
		<table border="1"> <tr> <td>i</td> <td>Above 100</td> <td>1</td> </tr> <tr> <td>ii</td> <td>60-99</td> <td>3</td> </tr> <tr> <td>iii</td> <td>30-59</td> <td>5</td> </tr> <tr> <td>iv</td> <td>1-29</td> <td>6</td> </tr> </table>	i	Above 100	1	ii	60-99	3	iii	30-59	5	iv	1-29	6		
i	Above 100	1														
ii	60-99	3														
iii	30-59	5														
iv	1-29	6														
10	Source of Raw Material	<table border="1"> <tr> <td rowspan="2">i</td> <td rowspan="2">Active ingredient</td> <td>Original Manufacture/research molecule /FDA approved</td> <td>5</td> </tr> <tr> <td>Others</td> <td>3</td> </tr> <tr> <td rowspan="2">ii</td> <td rowspan="2">Excipient</td> <td>Original Manufacture/research molecule /FDA approved</td> <td>5</td> </tr> <tr> <td>Others</td> <td>3</td> </tr> </table>	i	Active ingredient	Original Manufacture/research molecule /FDA approved	5	Others	3	ii	Excipient	Original Manufacture/research molecule /FDA approved	5	Others	3	10	Attach certificate
i	Active ingredient	Original Manufacture/research molecule /FDA approved			5											
		Others	3													
ii	Excipient	Original Manufacture/research molecule /FDA approved	5													
		Others	3													
11		Obtained marks=	Total = 70													